REG - ValiRx PLC - Holding(s) in Company <Origin Href="QuoteRef">VALX.L</Origin>
RNS Number : 0104BValiRx PLC04 January 2018TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:
ValiRx PLC
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)
Non-UK issuer
X
2. Reason for the notification (please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights
X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify)iii:
3. Details of person subject to the notification obligationiv
Name
YA II CD, Ltd.
City and country of registered office (if applicable)
4. Full name of shareholder(s) (if different from 3.)v
Name
Jarvis Investment Management Ltd
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reachedvi:
29 December 2017
6. Date on which issuer notified (DD/MM/YYYY):
3 January 2018
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A)
% of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)Total of both in % (8.A + 8.B)
Total number of voting rights of issuervii
Resulting situation on the date on which threshold was crossed or reached
6.99%
6.99%
399,062,717
Position of previous notification (if
applicable)
Less than 3%
Less than 3%
8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii
A: Voting rights attached to shares
Class/type of
sharesISIN code (if possible)
Number of voting rightsix
% of voting rights
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
Ordinary Shares (GB00BWWYSP41)
27,903,383
0
6.99%
0
SUBTOTAL 8. A
27,903,383
6.99%
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrument
Expiration
datexExercise/
Conversion PeriodxiNumber of voting rights that may be acquired if the instrument is
exercised/converted.
% of voting rights
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrument
Expiration
datexExercise/
Conversion Period xiPhysical or cash
settlementxii
Number of voting rights
% of voting rights
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)X
Namexv
% of voting rights if it equals or is higher than the notifiable threshold
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold
Total of both if it equals or is higher than the notifiable threshold
Yorkville Advisors Global II, LLC
6.99%
6.99%
Yorkville Advisors Global, LP
6.99%
6.99%
YA II CD, Ltd.
6.99%
6.99%
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional informationxvi
The Ordinary Shares are held by Jarvis Investment Management in CREST for the benefit of YA II CD, Ltd.
The shareholder is the holder of Convertible Note Instrument dated 30 November 2016. The shareholder submitted conversion notices to the Issuer (the "Conversion Shares") for 17,130,106 Ordinary Shares on 29 November 2017, 20,349,169 Ordinary Shares on 6 December 2017, 10,285,760 Ordinary Shares on 8 December 2017, and 25,222,857 Ordinary Shares on 21 December 2017 totalling 72,987,892 Conversion Shares plus 2,680,526 shares already held by the shareholder which represented 18.96% of the aggregate voting rights of the Issuer. 47,765,035 of the Conversion Shares were sold by the shareholder to independent third parties between 30 November 2017 and 3 January 2018 (the "Trades"). The Conversion Shares were issued on 29 December 2017 and 3 January 2018 and were used to settle the Trades. Jarvis is currently long 27,903,383 shares of the Issuer as of 3 January 2018. This notification of major holdings is being filed in connection with the receipt and disposal of the Conversion Shares in connection with the Trades.
Place of completion
Mountainside, New Jersey, USA
Date of completion
3 January 2018
This information is provided by RNSThe company news service from the London Stock ExchangeENDHOLUSUSRWNAARAR
Recent news on ValiRx
See all newsREG - ValiRx PLC - Director/PDMR Shareholding
AnnouncementREG - ValiRx PLC - ValiRx forms ValiRx Animal Health Ltd subsidiary
AnnouncementREG - AIM - AIM Notice - 23/01/2026
AnnouncementREG - ValiRx PLC - Exercise of Warrants
AnnouncementREG - ValiRx PLC - New Evaluation and Material Transfer Agreement
Announcement